ライフサイエンスコーパス: panretinal

1 year, therapy significantly reduced the mean panretinal (3.9% vs. 5.8%; P = 0.002) and macular (6.2%

2 mean quantitative leakage index was 3.5% for panretinal, 6.6% for macular, 4.8% for posterior pole, 3

3 zonal sparing (grade 2), and 35% (12/34) had panretinal alterations (grade 3).

4 Panretinal analyses were not linked to DME as strongly.

5 count and ischemic index were quantified in panretinal and macular regions.

6 MD, supporting the claim that the disease is panretinal and not macula only.

7 pheral retinal NV severity and incidence and panretinal arteriole and venule tortuosity indexes (TI(a

8 the intent of generating a rapid noninvasive panretinal assessment of ocular inflammation.

9 mild, isolated macular involvement to severe panretinal degeneration with abnormal ERG.

10 the vascular arcades, and 4 patients (11.1%) panretinal degeneration.

11 entan admix both produced similar (P > 0.05) panretinal DeltaPo(2).

12 On day 20, the panretinal deltaPO2 of the room air-recovered group (125

13 The panretinal deltaPO2 value for the SOR group (87 +/- 5 mm

14 Also, control and diabetic LEW rat panretinal DeltaPO2(t1-ra) were lower (P < 0.05) than in

15 diabetic LEW rats, a supernormal (P < 0.05) panretinal DeltaPO2(t2-t1) was found that could be corre

16 beyond the macula, suggesting that AMD is a panretinal disease.

17 ated a 63-year-old woman demonstrating acute panretinal dysfunction after intravitreous ocriplasmin i

18 Ocriplasmin injection may lead to acute panretinal dysfunction in some eyes, but the mechanism o

19 phy leakage was measured in 5 retinal zones: panretinal (entire retina), central macular (3-disc diam

20 oxygen physiopathology unfolds in eyes with panretinal hypoperfusion courtesy of the transparent ocu

21 .75%), and PDR (mean = 5.84%); P<2x10(-16)], panretinal ischemic index [mild NPDR (mean = 0.95%, mode

22 A numeric reduction in panretinal ischemic index and area was noted.

23 Panretinal ischemic index decreased between baseline and

24 The mean panretinal ischemic index demonstrated a small but likel

25 Panretinal ischemic index did not demonstrate any signif

26 Panretinal ischemic index did not improve and trended to

27 Panretinal leakage index, panretinal ischemic index, and panretinal microaneurysm

28 those with regressed ROP following bilateral panretinal laser photocoagulation (n = 37; median gestat

29 ive diabetic retinopathy has been managed by panretinal laser photocoagulation (PRP) for the past 40

30 Panretinal laser photocoagulation (PRP) was shown to be

31 Panretinal laser photocoagulation is the cornerstone of

32 ailable to all patients starting at month 3; panretinal laser was available as necessary.

33 Panretinal leakage index [mild NPDR (mean = 0.51%), mode

34 g-based qUWFA analysis platform was used for panretinal leakage index assessment and differentiation

35 The primary end point was the mean change in panretinal leakage index at month 12 from baseline as me

36 Mean panretinal leakage index improved significantly, decreas

37 tween both baseline macular leakage area and panretinal leakage index with IRF volume, SRF volume, an

38 Angiographic parameters included panretinal leakage index, ischemic index, and microaneur

39 rs demonstrates a significant improvement in panretinal leakage index, leakage area, and MA burden in

40 Panretinal leakage index, microaneurysm count, and ische

41 Panretinal leakage index, panretinal ischemic index, and

42 Mean panretinal leakage index, zonal leakage area, and panret

43 jections resulted in a dramatic reduction in panretinal leakage index.

44 Panretinal leakage was associated with DRSS (mean 2.2% f

45 tinal leakage index, zonal leakage area, and panretinal MA count improved significantly between basel

46 ), and PDR (mean = 9.53%); P<2x10(-16)], and panretinal microaneurysm count [mild NPDR (mean = 36), m

47 eakage index, panretinal ischemic index, and panretinal microaneurysm count are associated with DR se

48 Panretinal or focal endolaser photocoagulation was perfo

49 7D (MBDL) or 35B to 53E (MBCU), and no prior panretinal or focal photocoagulation in at least one eye

50 /cone/cone-rod dystrophy, "MCCRD group") and panretinal or peripheral dysfunction (retinitis pigmento

51 gly support an association between subnormal panretinal oxygenation ability and increased NV risk in

52 occurred but with an unexpected decrease in panretinal oxygenation ability.

53 ance imaging (MRI) was used to determine the panretinal oxygenation response (deltaPO2, mm Hg) to a c

54 ing the period when lesions are present, the panretinal oxygenation response remained significantly (

55 s, a significant (P < 0.05) reduction in the panretinal oxygenation response was observed in the gala

56 s exhibit a grainy retina that progresses to panretinal patches of depigmentation.

57 compared with baseline, as well as the mean panretinal perivascular leakage index (1.5% vs. 2.3%; P

58 ercept (100 participants) or vitrectomy with panretinal photocoagulation (105 participants).

59 bevacizumab, sub-Tenon's triamcinolone, and panretinal photocoagulation (PRP) after cataract surgery

60 termine the validity of self-report of prior panretinal photocoagulation (PRP) and focal photocoagula

61 diabetic retinopathy (PDR) interventions of panretinal photocoagulation (PRP) and intravitreal injec

62 clinical study was to compare the effect of panretinal photocoagulation (PRP) associated with intrav

63 retinopathy (PDR) treated to stability with panretinal photocoagulation (PRP) continue to lose visio

64 Panretinal photocoagulation (PRP) for proliferative diab

65 ate the efficacy and safety of anti-VEGF and panretinal photocoagulation (PRP) for the treatment of p

66 Eyes without preexistent panretinal photocoagulation (PRP) had a higher risk to u

67 ing neovascularization (NV) before and after panretinal photocoagulation (PRP) in eyes with treatment

68 ges in retinal nonperfusion before and after panretinal photocoagulation (PRP) in treatment-naive eye

69 thelial growth factor (VEGF) injections plus panretinal photocoagulation (PRP) is a common approach f

70 Panretinal photocoagulation (PRP) is the standard treatm

71 y have a variable response to treatment with panretinal photocoagulation (PRP) or anti-vascular endot

72 betic retinopathy (PDR) in eyes treated with panretinal photocoagulation (PRP) or ranibizumab.

73 emorrhage on presentation (P = .001), and no panretinal photocoagulation (PRP) treatments (P < .001).

74 emorrhage on presentation (P = .001), and no panretinal photocoagulation (PRP) treatments (P < .001).

75 h newly diagnosed high-risk PDR treated with panretinal photocoagulation (PRP) using either argon gre

76 ntravitreal aflibercept (IVA) injection with panretinal photocoagulation (PRP) versus early vitrectom

77 Adjuvant preoperative therapy with panretinal photocoagulation (PRP) versus no PRP (0.95 vs

78 ity (VA) over 24 weeks after vitrectomy with panretinal photocoagulation (PRP) vs aflibercept in a ra

79 more common among eyes assigned initially to panretinal photocoagulation (PRP) vs anti-vascular endot

80 mab is a reasonable treatment alternative to panretinal photocoagulation (PRP) when managing prolifer

81 re recorded, including anti-VEGF injections, panretinal photocoagulation (PRP), and surgical interven

82 al treatments including PPV, injections, and panretinal photocoagulation (PRP), as well as visual acu

83 PDR based on graded fundus photographs, (2) panretinal photocoagulation (PRP), or (3) pars plana vit

84 rative DR (NPDR), proliferative DR (PDR) and panretinal photocoagulation (PRP).

85 erative diabetic retinopathy (PDR) following panretinal photocoagulation (PRP).

86 d, though somewhat disorganized, as in human panretinal photocoagulation (PRP).

87 c retinopathy (PDR), previously treated with panretinal photocoagulation (PRP).

88 (SS) OCT angiography (OCTA) before and after panretinal photocoagulation (PRP).

89 All patients underwent panretinal photocoagulation (PRP).

90 ovascularization is best managed by applying panretinal photocoagulation after the first appearance o

91 s followed by immunosuppressants, along with panretinal photocoagulation and intravitreal ranibizumab

92 lar endothelial growth factor injections and panretinal photocoagulation are important to prevent neo

93 BCVA, early PPV, and absence of preoperative panretinal photocoagulation as significant predictors of

94 cluding visual acuity improvement, increased panretinal photocoagulation completion rates, and reduce

95 had vitreous hemorrhage from PDR precluding panretinal photocoagulation completion.

96 Panretinal photocoagulation could be initiated for failu

97 bercept, 2 mg, vs pars plana vitrectomy plus panretinal photocoagulation for nonclearing vitreous hem

98 ersus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic R

99 The patient underwent panretinal photocoagulation in both eyes with regression

100 Panretinal photocoagulation is designed to increase reti

101 n with intravitreal anti-VEGF medication and panretinal photocoagulation may help to prevent addition

102 Panretinal photocoagulation monotherapy was associated w

103 ween conversion to proliferative disease and panretinal photocoagulation or first treatment, and loss

104 Panretinal photocoagulation or intravitreous ranibizumab

105 Panretinal photocoagulation rates declined from 784/1000

106 Panretinal photocoagulation rates declined from 784/1000

107 Panretinal photocoagulation rates did not significantly

108 Panretinal photocoagulation rates in diabetic macular ed

109 Panretinal photocoagulation rates in diabetic macular ed

110 thy type, number of intravitreal injections, panretinal photocoagulation sessions, or photocoagulatio

111 In case of retinal ischemia, panretinal photocoagulation should be initiated soon to

112 line visual acuity, baseline hemoglobin A1c, panretinal photocoagulation status, and cumulative anti-

113 Panretinal photocoagulation treatment patterns and clini

114 Panretinal photocoagulation treatments declined from 109

115 Diabetic Macular Edema), Protocol S (Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizu

116 Panretinal photocoagulation was shown to be beneficial f

117 The absence of panretinal photocoagulation was the primary significant

118 intravitreous injections of bevacizumab and panretinal photocoagulation were administered, the new v

119 acuity (VA) (P = 0.001), failure to receive panretinal photocoagulation within 2 weeks of surgery (P

120 nce, 4%; 95% CI, -4% to 13%) and of complete panretinal photocoagulation without vitrectomy by 16 wee

121 in eyes without PDR at baseline, (3) having panretinal photocoagulation, (4) experiencing vitreous h

122 rative diabetic retinopathy (PDR) usually is panretinal photocoagulation, an inherently destructive t

123 Treatment for PDR, panretinal photocoagulation, is inherently destructive a

124 des for intravitreal injection, focal laser, panretinal photocoagulation, laterality of procedure, ra

125 endothelial growth factor (VEGF) injection, panretinal photocoagulation, or both for retinal ischemi

126 Before panretinal photocoagulation, patients received one of se

127 Following panretinal photocoagulation, subjective pain was assesse

128 iteria were previous intravitreal injection, panretinal photocoagulation, vitrectomy, central-involvi

129 However, heightened panretinal photocoagulation-related pain in females, pat

130 algesic efficacy in nearly all patients with panretinal photocoagulation-related pain, while nepafena

131 benefit in favor of initial vitrectomy with panretinal photocoagulation.

132 teristics on pain perception associated with panretinal photocoagulation.

133 eloped in 4 patients, which was managed with panretinal photocoagulation.

134 especially in eyes that are nonresponsive to panretinal photocoagulation.

135 cludes placement or confirmation of complete panretinal photocoagulation.

136 intravitreous aflibercept vs vitrectomy with panretinal photocoagulation.

137 -enabled feature extraction system generated panretinal quantitative UWFA metrics, including leakage,

138 Panretinal TI(a) and TI(v) were increased over control v

139 y associated with peripheral NV severity and panretinal TI(a).

140 s associated with peripheral NV severity and panretinal TI(a).

141 Panretinal TI(v) was not correlated with intraretinal io